Johnson & Johnson (JNJ)vsEnvista Holdings Corp (NVST)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
NVST
Envista Holdings Corp
$25.90
-2.23%
HEALTHCARE · Cap: $4.22B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3443% more annual revenue ($96.36B vs $2.72B). JNJ leads profitability with a 21.8% profit margin vs 1.7%. JNJ trades at a lower P/E of 26.3x. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
NVST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+57.7%
Fair Value
$71.58
Current Price
$25.90
$45.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Earnings expanding 3146.0% YoY
15.0% revenue growth
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
ROE of 1.6% — below average capital efficiency
1.7% margin — thin
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : NVST
The strongest argument for NVST centers on Price/Book, EPS Growth, Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NVST
The primary concerns for NVST are Return on Equity, Profit Margin, P/E Ratio. A P/E of 92.5x leaves little room for execution misses. Thin 1.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NVST is a value play — different risk/reward profiles.
NVST carries more volatility with a beta of 0.98 — expect wider price swings.
NVST is growing revenue faster at 15.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 56/100), backed by strong 21.8% margins. NVST offers better value entry with a 57.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Envista Holdings Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?